Sign in

You're signed outSign in or to get full access.

Thompson S. Dent

Lead Independent Director at HEALTHSTREAM
Board

About Thompson S. Dent

Thompson S. Dent, 74, has served on HealthStream’s Board since 1995 and is the Company’s Lead Independent Director since December 15, 2014. He holds a Masters in Healthcare Administration from The George Washington University and a Bachelor’s degree in Business from Mississippi State University. He is standing for re-election in 2025 as a Class I Director and, if elected, will serve until the annual meeting in 2028 .

Past Roles

OrganizationRoleTenureLocationNotes
Urgent Team, LLCChief Executive Officer & ChairmanSince 2013Independent operator of urgent care centers
Re: Cognition Health, Ltd.Co-founder & Executive ChairmanSince 2010London, EnglandProvider for cognitive disorders and clinical trials in Alzheimer’s and other CNS diseases
MedTel International CorporationExecutive Chairman & Chief Executive Officer2004–2008Nashville, TNInternational diagnostic imaging company

External Roles

OrganizationTypeRoleTenure
Urgent Team, LLCPrivate companyCEO & ChairmanSince 2013
Re: Cognition Health, Ltd.Private companyCo-founder & Executive ChairmanSince 2010

Board Governance

  • Lead Independent Director with a Board-approved charter; responsibilities include presiding at meetings without the CEO/Chair present, calling meetings of independent directors, serving as liaison, and approving Board agendas and information flow .
  • Committee assignments: Chair, Nominating and Corporate Governance Committee; members during 2024 were Dent (Chair), Alex Jahangir, M.D., and Deborah Taylor Tate; all are Nasdaq independent .
  • Attendance: In 2024 the Board held 7 meetings; Nominating and Corporate Governance Committee held 6; each director attended 100% of Board and respective committee meetings in aggregate; independent directors meet in executive session at least twice annually .
  • Independence: The Board determined Dent is independent under Nasdaq rules; HSTM’s standing committees are comprised solely of independent directors .

Fixed Compensation

Metric20232024
Fees Earned Paid in Cash ($)37,500 40,000
Fees Earned Paid in Stock ($)
Stock Awards ($)80,508 81,999
Total ($)118,008 121,999

Notes: In 2023, the director cash compensation structure included a flat attendance fee, annual retainer, and additional retainers for certain roles (Audit Chair; Lead Independent Director/Nominating & Corporate Governance Chair; Compensation Chair); amounts were unchanged from 2022 .

Performance Compensation

Metric20232024
RSUs Granted (#)3,377 3,018
Grant Date Fair Value ($)80,508 81,999
Vesting Schedule3 equal annual installments over 3 years 3 equal annual installments over 3 years
Outstanding RSUs at FY-end (#)6,618 6,419

Notes: No performance-conditioned equity (e.g., PSUs) disclosed for non-employee directors; awards are time-based RSUs .

Other Directorships & Interlocks

EntityRelationship to HSTMNature of TransactionGovernance Handling
Entities where Dent serves as an executive officerCustomer of HSTM SaaS offeringsOrdinary-course vendor agreements for software-as-a-service; no consulting or professional servicesEntered at arm’s-length without Dent’s participation; reviewed under Related-Party Transactions Policy; Board concluded relationships were not material and did not impair independence .

Expertise & Qualifications

  • Decades of healthcare services leadership; service on numerous healthcare company boards and committees cited by the Company as qualifications .
  • Education:
    • Masters in Healthcare Administration, The George Washington University .
    • Bachelor’s in Business, Mississippi State University .

Equity Ownership

MetricAs of
Beneficially owned shares (#)134,695 (based on 30,525,266 shares outstanding)
Ownership %Less than 1%
Outstanding RSUs (#)6,419 at FY-end 2024

Governance Assessment

  • Board effectiveness: Dent provides strong independent leadership as Lead Independent Director with defined authority; he chairs the Nominating & Corporate Governance Committee overseeing board skills assessments, self/peer evaluations, ESG oversight, and succession planning processes .
  • Independence and attendance: Explicitly deemed independent; perfect attendance in 2024 across Board and committees; independent directors hold executive sessions at least twice per year .
  • Alignment and pay mix: Director compensation is predominantly equity-based RSUs ($81,999 in 2024) alongside modest cash fees ($40,000), aligning interests with shareholders through multi-year vesting; multi-year continuity with small YoY increases suggests stability in director pay .
  • Shareholder support signals: In 2025, Dent received 23,834,909 FOR and 2,870,017 WITHHELD votes; comparator Class I nominees received 26,587,086 FOR/117,840 WITHHELD (Beard) and 24,871,079 FOR/1,833,847 WITHHELD (Tate). Say-on-pay was approved (FOR 25,224,051; AGAINST 1,475,091) .
  • Potential conflicts and mitigation: HSTM maintains vendor agreements with entities where Dent is an executive officer; these are SaaS-only, arms-length, and reviewed under the Related-Party Transactions Policy; the Board concluded no material relationships and maintained independence determinations .

RED FLAGS to monitor

  • Related-party exposure via vendor agreements with entities led by Dent—currently mitigated by arms-length terms, policy oversight, and non-materiality determinations; continue monitoring for changes in scope or economics .
  • 2025 director election withhold votes for Dent (2,870,017) were higher than for Beard (117,840) and Tate (1,833,847), a relative signal to watch for investor sentiment on governance or independence perceptions .